{"nctId":"NCT01395524","briefTitle":"A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation","startDateStruct":{"date":"2011-07"},"conditions":["Opioid-Induced Constipation (OIC)"],"count":302,"armGroups":[{"label":"NKTR-118 12.5mg","type":"EXPERIMENTAL","interventionNames":["Drug: NKTR-118"]},{"label":"NKTR-118 25mg","type":"EXPERIMENTAL","interventionNames":["Drug: NKTR-118"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"NKTR-118","otherNames":[]},{"name":"NKTR-118","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have completed the 12-week study D3820C00004 through Visit 8.\n* Provision of written informed consent prior to any study-specific procedures.\n* Men and women who were between the ages of \\>18 and \\<85 years at the time of the screening visit for study D3820C00004.\n* Continuing to receive a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more other opioid therapies.\n* Willingness to continue abstinence from all laxatives and other bowel regimens including prune juice and herbal products throughout this additional 12-week treatment period, and to use only bisacodyl as rescue medication if a bowel movement (BM) has not occurred within at least 72 hours of the last recorded BM.\n\nExclusion Criteria:\n\n* Patients receiving opioid regimen for treatment of pain related to cancer.\n* History of cancer within 5 years from the screening visit of study D3820C00004 with the exception of basal cell cancer and squamous cell skin cancer.\n* Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.\n* Other issues related to the gastrointestinal tract that could impose risk to the patient.\n* Pregnancy or lactation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"84 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Patients Experiencing at Least One Adverse Event (AE)","description":"The incidence of patients experiencing at least one AE during the randomized treatment and follow-up periods was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM)","description":"The PAC-SYM questionnaire is a 12-item questionnaire that evaluates the severity of symptoms of constipation in 3 domains (stool, rectal, and abdominal symptoms) on a 5-point Likert scale ranging from 0 (absent) to 4 (very severe) in the 2 weeks (14 days) prior to assessment. Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items (ie, symptoms). The range of the domain or total score is 0 (response is 'absent' for each item) to 4 (response is 'very severe' for each item). A negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.71"},{"groupId":"OG001","value":"-0.9","spread":"0.85"},{"groupId":"OG002","value":"-0.8","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.85"},{"groupId":"OG001","value":"-0.7","spread":"0.97"},{"groupId":"OG002","value":"-0.7","spread":"0.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.84"},{"groupId":"OG001","value":"-0.7","spread":"0.84"},{"groupId":"OG002","value":"-0.6","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.90"},{"groupId":"OG001","value":"-1.1","spread":"1.04"},{"groupId":"OG002","value":"-0.9","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL)","description":"The PAC-QOL scale is a 28-item self-report instrument designed to evaluate the burden of constipation on patients' everyday functioning and well-being in the 2 weeks (14 days) prior to assessment. Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). The instrument can be used to generate an overall score, but is also reported to assess 4 specific constipation-related domains including: 1) Worries and concerns (11 items), 2) Physical discomfort (4 items), 3) Psychosocial discomfort (8 items), and 4) Satisfaction (5 items). Each domain score is the mean of the non-missing items for that domain. The total score is the mean of all non-missing items. The range of the domain or total score is 0 (response is 'not at all' for each item) to 4 (response is 'extremely' for each item). A negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.89"},{"groupId":"OG001","value":"-0.9","spread":"0.82"},{"groupId":"OG002","value":"-0.8","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.97"},{"groupId":"OG001","value":"-1.1","spread":"0.97"},{"groupId":"OG002","value":"-1.0","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.97"},{"groupId":"OG001","value":"-0.7","spread":"0.86"},{"groupId":"OG002","value":"-0.6","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.09"},{"groupId":"OG001","value":"-0.9","spread":"0.91"},{"groupId":"OG002","value":"-0.7","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.14"},{"groupId":"OG001","value":"-1.3","spread":"1.22"},{"groupId":"OG002","value":"-1.1","spread":"1.21"}]}]}]},{"type":"PRIMARY","title":"Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)","description":"The incidence of patients experiencing AEs that resulted in discontinuation of IP during the randomized treatment or follow-up periods was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Patients Experiencing Severe Adverse Events (SAEs)","description":"The incidence of patients experiencing SAEs during the randomized treatment and follow-up periods was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":94},"commonTop":["DIARRHOEA","SINUSITIS","URINARY TRACT INFECTION","ARTHRALGIA","NAUSEA"]}}}